Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study

  title={Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study},
  author={Christoph Schulz and Volker Heinemann and Kathrin Heinrich and Michael Haas and Julian Walter Holch and Alessia Fraccaroli and Swantje Held and Jobst Christian von Einem and Dominik Paul Modest and Ludwig Fischer von Weikersthal and Frank Kullmann and Markus Moehler and Werner Scheithauer and Andreas Jung and Sebastian Stintzing},
  journal={Anti-Cancer Drugs},
  pages={856 - 865}
Magnesium wasting is a frequent side effect of epidermal growth factor receptor (EGFR)-antibody treatment as magnesium-absorption mechanisms are dependent on EGFR signaling. EGFR-inhibition results in decreased renal reabsorption. There is evidence that hypomagnesemia during cetuximab treatment correlates with response. The prognostic role of hypomagnesemia during bevacizumab treatment has not been studied yet. Here, we evaluate the prognostic value of hypomagnesemia in patients with metastatic… Expand
Imbalance of Mg Homeostasis as a Potential Biomarker in Colon Cancer
This study found a significantly higher content of total Mg in CRC samples when compared to non-tumoural tissues and evidenced an uncertain correlation between Mg transporters expression and colon malignancies. Expand
Drinking from the firehose - A clinician's perspective on the challenges of delivering biomarker-driven care in routine practice.
The '4Cs' are presented to interrogate the biomarker literature, including analysis of the credibility, consistency, completeness and context of the biomarkers research, and a framework to frame the literature moving forward is suggested. Expand


Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.
Early hypomagnesemia could be a predictor of efficacy and outcome in patients treated with cetuximab in a cohort of patients affected by advanced colorectal adenocarcinoma KRAS wild-type cetUXimab-treated patients. Expand
Early Magnesium Reduction in Advanced Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan as Predictive Factor of Efficacy and Outcome
The results confirm that cetuximab treatment may induce a reduction of Mg2+ circulating levels and offer the first evidence that Mg 2+ reduction may represent a new predictive factor of efficacy in advanced colorectal cancer patients treated with cetUXimab plus irinotecan. Expand
Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer
Hypomagnesemia may become a predicting factor for therapeutic effects of anti-EGFR monoclonal antibody in mCRC patients and no significant difference in both ORR and median TTF was observed between patients with and without acneiform rash. Expand
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
An updated analysis of the TRIBE study aimed to provide mature results for overall survival-a secondary endpoint-and report treatment efficacy in RAS and BRAF molecular subgroups, and assessed the secondary endpoint of overall survival in the main cohort. Expand
Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
The final analysis of ASPECCT showed panitumumab was non-inferior to cetuximab for overall survival (OS) in patients with chemotherapy-refractory, wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). Expand
Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels
Serum levels of magnesium were lower when cetuximab was combined with a platinum derivative, and as hypomagnesemia was more prominent in patients receiving platinum agents, magnesium measurements may be advised in these patients. Expand
Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.
In contrast to prior reports, cetuximab-induced hypomagnesemia was associated with poor OS, even after adjustment for grade of rash, in patients with pretreated advanced CRC. Expand
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
The association with longer overall survival suggests that FOLFIRI plus cetuximab could be the preferred first-line regimen for patients with KRAS exon 2 wild-type metastatic colorectal cancer. Expand
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Adding aflibercept to first-line mFOLFOX6 did not increase efficacy but was associated with higher toxicity, and no difference in PFS rate was observed between treatment groups. Expand
Cetuximab therapy and symptomatic hypomagnesemia.
It is suggested that, when fatigue or hypocalcemia is encountered during cetuximab therapy, serum magnesium level be measured and repleted as necessary, and symptoms may be rapidly ameliorated with supplementation. Expand